


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**

**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT  
ENTERING INTO LICENSE AGREEMENT**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”) announces that on 21 September 2022, Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“**CTTQ**”), a subsidiary of the Company, has entered into a definitive license agreement (the “**Agreement**”) with Inventiva S.A. (“**Inventiva**”) to develop, manufacture, and commercialize lanifibranor (the “**Product**”), Inventiva’s lead product candidate, for the treatment of non-alcoholic steatohepatitis (“**NASH**”) and potentially other metabolic diseases in mainland China, Hong Kong, Macau and Taiwan (“**Greater China**”). Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, mucopolysaccharidosis and other diseases with significant unmet medical needs. In exchange for receiving an exclusive license for the Product in Greater China, CTTQ will pay Inventiva an upfront payment of US\$12 million and up to US\$40 million in potential clinical and regulatory milestone payments. Subject to regulatory approval and depending on net sales in Greater China, CTTQ will pay additional commercial milestones and tiered royalties on net sales.

**RATIONALE**

The addition of the Product to the Company’s pipeline will further enrich our innovative pipeline, complete our layout in field of NASH and provide better treatment for NASH patients in China. NASH is an area of high unmet medical need with no approved treatments currently available and one of the fastest growing causes of liver cirrhosis and liver cancer globally. Currently there is no approved treatment in China, and therefore by 2025, the new incidence of NASH in China is expected to reach 2 million every year. The Product is a late stage asset currently in Phase III clinical trials in the US, thereby it is expected to be the first FDA approved oral NASH treatment with potentially best in class efficacy, to address a large clinical unmet need in the global NASH market.

## ABOUT THE PRODUCT

The Product is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptors that regulate multiple process related to lipid metabolism, glucose homeostasis, and insulin signaling. The Product is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPAR $\alpha$  and PPAR $\delta$ , and a partial activation of PPAR $\gamma$ . While there are other PPAR agonists that target only one or two PPAR isoforms for activation, the Product is the most advanced pan-PPAR agonist in clinical development for the treatment of NASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and pre-clinical studies to date.

In the Phase IIb NATIVE, the lanifibranor met both the primary and key secondary endpoints for the treatment of F1-F3 NASH patients, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASH and was published in the New England Journal of Medicine. Lanifibranor is the first orally available drug candidate to achieve statistically significant results on the two recommended primary endpoints by U.S. Food and Drug Administration (FDA) and European Medicine Agency (EMA), relevant for seeking U.S. accelerated approval and EU conditional approval during Phase III clinical development. NATiV3, a pivotal phase III trial of lanifibranor in F2/F3 NASH is currently ongoing with first clinical trial sites initiated and patients screened in the United States. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 22 September 2022

*As at the date of this announcement, the Board of the Company comprises eight executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*